Which of the following is considered first-line therapy for reducing the risk of atherosclerotic cardiovascular...

ATP4 found that the use of statins for prevention of ASCVD is extensive and consistent. Statin therapy is recommended for patients at a higher risk of ASCVD who are most likely to experience a net benefit in terms of the potential for risk reduction vs the potential for adverse effects. Non-statin therapies do not provide

sufficient benefits in the reduction of ASCVD risk in regards to their potential for adverse effects.